AB0435 REAL WORLD DATA OF A PATIENT COHORT WITH RHEUMATOID ARTRITIS TREATED WITH JAK/STAT INHIBITORS
Background: We present the real World data of a patient cohort with rheumatoid arthritis (RA) that received one of the two JAK/STAT inhibitors approved by the EMA for this indication. Objectives: To describe the Real World Data of a patient cohort attending Rheumatology consult of a reference hospital in Valencia with RA diagnosis and that were treated with JAK/STAT inhibitors. Methods: A descriptive retrospective study was carried out. There were revised medical histories of 28 patients with a RA diagnosis that attended our consults between 2017 and 2018. All 28 patients were JAK/STAT treatment receivers of one of the two JAK/STAT inhibitors approved: Tofacitinib 10 mg oral QD or Bariticinib 4 mg oral QD. There were collected patient baseline demographic data: sex, age, BMI, activity disease score measured by DAS28 CRP and visual pain analogue scale for patient's assessment (VAS) In addition, there were collected the previous synthetic(s) and biological (s) DMARD treatments, as well as the associated treatments. Efficacy and security were also analysed. There were assessed serum biochemical variables, among them acute phase reactants such as CRP and and ESR Results: The study population consisted in 28 patients with the following distribution: M/F Mean age (years) BMI (kg/m2) Baricitinib Tofacitinib DAS28/CRP (at de begining) Mean treatment time (days) 12 (42%/16 (58% 58.39 30.12 9 (32.14% 19 (67.85% 4.81 230.11 With regards to the previous treatments received, we obtained the following results: Previous DMARDb Previous DMARDc 3TB 2TB 1TB Naive 3 2 1 Naive 5 3 10 10 2 9 15 2 DMARDb: Number of previous biological treatment DMARDc: Number of synthetic previous treatments With regards to efficacy, there were collected 6 treatment withdrawals: 1 primary treatment failure (in Tofacitinib Group) and 5 secondary treatment failures (1 in Baricitiib Group and 4 in Tofacitinib Group) and the mean treatment duration was 152 days. Conclusion: Despite the study population was small and the follow up time was short, we highlight in our patients that both JAK inhibitor alternatives have shown a security and efficacy profile similar to the results shown in pivotal clinical trials. Despite the previous biological treatment failure and obesity are considered as predictors of bad response to treatment, in our cohort did not represent a high risk to treatment failure, it can be an alternative in the same scenary. Disclosure of Interests: Isabel de la Morena Speakers bureau: Abbvie, Celgene, Pfzier, UCB, Ghebro, Roche, Sanofi, Janssen. Juan Alberto Paz Solarte Employee of: He is working at UCB since December 2018, when the patient recruitment ended. Speakers bureau: Abbvie, Roche, Pfzier, Novartis, Celgene, Amgen, MSD, Janssen, Diego Bedoya: None declared, Pilar Trenor Larraz: None declared
Abstracts Accepted for Publication